Learn About ALK-Positive Non-Small Cell Lung Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top ALK-Positive Non-Small Cell Lung Cancer Local Doctors?
SW
Saiama N. Waqar
Dr. Saiama N. Waqar
Oncology
Elite
Highly rated in
15
conditions
Oncology

BJC HealthCare

Division Of Oncology

10 Barnes W Dr 
Creve Coeur, MO 63141

Saiama Waqar is an Oncologist in Creve Coeur, Missouri. Dr. Waqar has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. She is also highly rated in 15 other conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer NCSLC, Small Cell Lung Cancer SCLC, and ALK-Positive Non-Small Cell Lung Cancer. She is licensed to treat patients in Missouri. Dr. Waqar is currently accepting new patients.

View Profile
DC
Dr. David R. Camidge
Oncology | Hematology | Internal Medicine
Elite
Highly rated in
12
conditions
Oncology
Hematology
Internal Medicine

UCHealth Medical Group

1665 Aurora Ct 
Aurora, CO 80045

David Camidge is an Oncologist and a Hematologist in Aurora, Colorado. Dr. Camidge is rated as an Elite doctor by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer NCSLC, Lung Cancer, and EGFR Positive Lung Cancer. He is licensed to treat patients in Colorado. Dr. Camidge is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
AC
Dr. Abraham Chachoua
Hematology Oncology | Oncology
Distinguished
Highly rated in
32
conditions
Hematology Oncology
Oncology

NYU Langone Health

Perlmutter Cancer Center - Sunset Park

5718 2nd Ave 
Brooklyn, NY 11220

Abraham Chachoua is a Hematologist Oncology specialist and an Oncologist in Brooklyn, New York. Dr. Chachoua has been practicing medicine for over 43 years and is rated as a Distinguished doctor by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer NCSLC. He is licensed to treat patients in New York. Dr. Chachoua is currently accepting new patients.

View Profile
View All Doctors
What are the Latest Advances for ALK-Positive Non-Small Cell Lung Cancer?
Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Condition: Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases
Journal: Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)
Treatment Used: Alectinib
Number of Patients: 2
Published: October 04, 2020
View publication
Summary: Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Condition: ALK-Positive Non-Small-Cell Lung Cancer
Journal: The Lancet. Oncology
Treatment Used: Lorlatinib
Number of Patients: 276
Published: November 11, 2018
View publication
Summary: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Tired of the same old research?
Check Latest Advances
View All Latest Advances
What are the latest ALK-Positive Non-Small Cell Lung Cancer Clinical Trials?
Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Brigatinib (Alunbrig®) in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) in Argentina
Status: Recruiting
Start Date: December 30, 2020
Intervention Type: Other
Study Drugs: Brigatinib
View Trial
Summary: The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC). Treatment with brigatinib and follow-up will be according to routine clinical practice.~Study doctors will review the participants' medical records at the start of the study, then at 12 and 24 we...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Who is this study for: Patients previously treated with 2nd generation ALK inhibitor
Status: Recruiting
Start Date: November 17, 2020
Intervention Type: Drug
Study Drugs: Lorlatinib
Phase: Phase 2
View Trial
Summary: This study includes patients diagnosed with a metastatic non small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) translocation. The standard treatment for patients with metastatic non small cell lung cancer with ALK translocation is represented by personalized treatment with drugs called ALK inhibitors. During the treatment with an ALK inhibitor, the tumour can start to grow again...
View All Clinical Trials